BioStock: Curasight committed to progressing pipeline

The partnership with Curium for diagnosis in prostate cancer is advancing and Curasight aims to accelerate the development of the therapeutic platform uTREAT in multiple indications to support its theranostic approach. The company is working hard to secure funding for its clinical plans for uTREAT and according to the company’s interim report for the first quarter results of 2024, hopes to announce news on the financing soon.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/curasight-committed-to-progressing-pipeline/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se